- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
GeneDx Holdings Corp. Shares Sold by William Blair Investment Management LLC
Institutional investor reduces stake in genomics company
Published on Mar. 2, 2026
Got story updates? Submit your updates here. ›
William Blair Investment Management LLC has reduced its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 25.2% during the third quarter, according to a recent SEC filing. The institutional investor now owns 1,220,138 shares of the company's stock, worth $131,458,000, after selling 411,264 shares.
Why it matters
This filing indicates a shift in institutional investment in GeneDx, a leading provider of genetic and genomic testing services. The reduction in William Blair's stake could signal broader market trends or changes in the company's outlook.
The details
According to the 13F filing, William Blair Investment Management LLC sold 411,264 shares of GeneDx stock during the third quarter. The firm now owns 4.22% of the company's outstanding shares, down from a previous stake of 5.65%.
- The filing covers the third quarter of the year.
The players
William Blair Investment Management LLC
An institutional investment management firm that has reduced its stake in GeneDx Holdings Corp.
GeneDx Holdings Corp.
A clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders.
The takeaway
This filing highlights the shifting landscape of institutional investment in the genomics industry, as major players like William Blair adjust their positions in companies like GeneDx. Investors will likely watch for further changes in institutional ownership and analyst sentiment around GeneDx as the company navigates the competitive genetic testing market.
